Washington, D.C. 20549


Pursuant to Section 13 or 15(d) of
The Securities Exchange Act of 1934

Date of Report (date of earliest event reported): August 10, 2020
 Natus Medical Incorporated
(Exact name of registrant as specified in its charter)
(Commission File Number)
Delaware 77-0154833
(State or other jurisdiction
of Incorporation)
 (I.R.S. Employer
Identification No.)
6701 Koll Center Parkway, Suite 120
Pleasanton, CA 94566
(Address of principal executive offices) (Zip Code)
(Registrant’s telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
 Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

                 Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying

with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered
Common Stock, $0.001 par value per shareNTUSThe Nasdaq Stock Market LLC
(The Nasdaq Global Market)

Item 1.01.
Entry into a Material Definitive Agreement.

On August 10, 2020, Natus Medical Incorporated (the “Company”) amended the terms of its five year credit agreement dated September 23, 2016 (the "Amended Credit Agreement") by and between the Company, JP Morgan Chase Bank, NA ("JP Morgan"), Citibank, NA ("Citibank"), and Wells Fargo Bank, NA ("Wells Fargo"). The Amended Credit Agreement extends the maturity date of the original agreement from September 23, 2021 to September 25, 2023, reduces the aggregate revolving credit facility from $225 million to $150 million, and amends certain covenants. As of August 11, 2020, a total of $87 million out of an available $150 million was outstanding under the Amended Credit Agreement.

The foregoing description of the Amended Credit Agreement does not purport to be complete and is qualified in its entirety by the terms of such Amended Credit Agreement. The Company intends to file the Amended Credit Agreement with the U.S. Securities and Exchange Commission as an exhibit to its next Quarterly Report on Form 10-Q.

Item 2.03.
Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant.

The information set forth under Item 1.01 is hereby incorporated by reference into this Item 2.03.

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Dated: August 11, 2020   By: /s/ B. Drew Davies
    Executive Vice President and Chief Financial Officer